サンプル依頼リスト カート
  • English
  • Korean
表紙：α1アンチトリプシン欠乏症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374771

α1アンチトリプシン欠乏症治療の世界市場-2023年～2030年

Global Alpha-1 Antitrypsin Deficiency Therapy Market -2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
α1アンチトリプシン欠乏症治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界のα-1抗トリプシン欠乏症治療市場は、様々な要因がそのダイナミクスに影響を及ぼしながら、長年にわたって大きな成長と変貌を遂げてきました。AAT欠乏症の場合、肺やその他の病気を発症する可能性が高くなります。AATは肝臓で産生されるタンパク質で、肺の防御を助ける。体内でAATが十分に生成されないと、肺は喫煙、大気汚染、環境粉塵による傷害を受けやすくなります。

特に新興経済諸国では、政府による投資や研究が先進的な製品や治療法の利用を引き続き促進し、世界のα1抗トリプシン欠乏症治療市場を押し上げると思われます。それぞれの革新的製品には、より良い管理のための増強療法などの新規治療法の使用が含まれます。

市場促進要因：市場抑制要因

増大療法に対する認可の増加

新興経済諸国は、高額の投資、所得水準、インフラ整備に牽引され、ヘルスケア分野の改善において急速な成長を遂げています。α-1抗トリプシン欠乏症治療薬に対する需要は、研究成果が良好であることから、いくつかの国々で大きな伸びを示しています。各国における製品上市のための様々な規制上の承認は、市場の成長を促進する重要な要因です。

2023年5月16日、グラスリア［α-1プロテイナーゼ阻害剤（人間）］は、重度の遺伝性α-1抗トリプシン欠乏症（AA）による肺気腫と臨床診断された成人における維持療法を伴う長期拡張療法として、スイスで販売承認を取得しました。

さらに、α-1抗トリプシン欠乏症の管理に対する新規治療薬や薬剤の利用が増加しています。人々の意識の高まりと革新的な製品開発のための研究の増加は、α-1抗トリプシン欠乏症治療薬市場の成長を促進する主な要因です。

増強療法に伴う副作用

α-1抗トリプシン増強療法の副作用はいくつか報告されているが、大多数は深刻な問題を経験することはないです。最も頻度の高い副作用は疲労やインフルエンザのような症状で、点滴後24時間も続くことがあります。点滴のペースを遅くすることで、このような症状が軽減されたり、消失したりすることがよくあります。

かゆみ、発疹、じんましん、呼吸困難、胸部圧迫感、喘鳴は、軽度のアレルギー反応に類似した症状の一部です。点滴の前にベナドリルなどの抗ヒスタミン剤を服用すれば、その多くは増強療法を続けることができます。アルファが増強療法を完全に中止しなければならないほど副作用がひどくなることは、ごくまれです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 増大療法に対する規制当局の承認拡大
      • 技術的進歩と開発の高まり
    • 抑制要因
      • 増強療法に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 価格分析
  • SWOT分析
  • 特許分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 治療法別

  • 増強療法
    • プロラスチン-C
    • アララスト
    • ゼマイラ
    • グラシア
  • 薬物療法
    • 気管支拡張薬
      • イプラトロピウム臭化物
      • テオフィリン
    • 抗生物質
      • ドキシサイクリン
      • ダプソン
  • 酸素療法
  • 禁煙療法
  • その他

第8章 投与経路別

  • 吸入
  • 静脈内投与

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Kamada Pharmaceuticals
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Takeda Pharmaceutical Company Limited
  • CSL
  • Vertex Pharmaceuticals Incorporated
  • Grifols
  • Arrowhead Pharmaceuticals, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Inhibrx, Inc.
  • Wave Life Sciences
  • Mereo Biopharma Group PLC

第13章 付録

目次
Product Code: PH7165

Overview

The global alpha-1 antitrypsin deficiency therapy market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The chance of developing lung and additional illnesses increases if the person have an AAT deficiency. AAT is a protein produced in the liver that aids in lung defense. The lungs are more vulnerable to injury from smoking, air pollution, and environmental dust if the body fails to produce enough AAT.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or therapies and boost the global alpha-1 antitrypsin deficiency therapy market. The respective innovative products includes the use of novel treatments such as augmentation therapy for better management.

Market Dynamics: Drivers & Restraints

Growing regulatory approvals for augmentation therapy

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for alpha-1 antitrypsin deficiency therapy owing to the positive outcomes in research. Various regulatory approvals for product launch among different countries will be a crucial factor driving the growth of the market.

On May 16, 2023, Glassia [Alpha-1 Proteinase Inhibitor (Human)] got approval for marketing in Switzerland for long-term augmentation along with maintenance treatment in adults having clinically diagnosed emphysema caused by severe hereditary Alpha-1 antitrypsin deficiency (AA), according to a report from Kamada Ltd., a commercial phase global biopharmaceutical business with a portfolio of marketed drugs indicated for rare and severe medical conditions.

Furthermore, the rising utilization of novel therapies or drugs for the management of alpha-1 antitrypsin deficiency. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the alpha-1 antitrypsin deficiency therapys market.

Side effects associated with the augmentation therapy

Although several negative effects of augmentation therapy have been recorded by alphas, the majority never experience any serious issues. The most frequent adverse reaction is fatigue or flu-like symptoms, which can persist for as long as 24 hours following an infusion. Slowing down the pace of infusion can frequently decrease or even get rid of these symptoms.

Itching, rash, hives, dyspnea, tightness in the chest, and wheezing are some of the symptoms that some Alphas have that resemble mild allergic reactions. If patients take an antihistamine like Benadryl prior to their infusions, many of those can continue getting augmentation therapy. Very seldom, adverse effects are bad enough to have an Alpha completely quit their augmentation medication.

Segment Analysis

The global alpha-1 antitrypsin deficiency therapy market is segmented based on therapy, route of administration, end user and region.

Augmentation Therapy segment accounted for approximately 43% of market share

Patients with significant alpha-1 antitrypsin (AAT) insufficiency who have emphysema may benefit from augmentation therapy, sometimes referred to as replacement therapy. The level of alpha-1 antitrypsin (AAT) in the lungs of patients having AAT deficiency is increased using alpha-1 antitrypsin protein obtained from the blood of healthy donors. AAT guards against lung damage caused by the immune system in healthy people. AAT augmentation therapy helps individuals with AAT deficiency increase the quantity of AAT in their lungs, preventing additional lung damage.

On July 13, 2023, a phase 3 clinical trial to ascertain whether alpha-1-antitrypsin (AAT) deficiency (alpha-1) individuals who have emphysema have a more gradual rate of lung tissue lack when handled weekly with two distinct dose regimens of Grifols Prolastin-C has reached its enrollment goal of 339 patients, according to Grifols, one of the world's top producers of plasma-derived medications.

Prolastin-C has the potential to substantially slow the development of emphysema in alpha-1 patients by increasing AAT protein levels via weekly administration of two successful dose levels compared to placebo, according to SPARTA, the largest randomized, placebo-controlled, double-blind, study on AAT augmentation treatment to date.

Geographical Penetration

North America accounted for around 38% of market share in 2022

Due to the rising need for alpha-1 antitrypsin deficiency therapy in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for alpha-1 antitrypsin deficiency therapy.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of therapies for management, and increase in pharmaceutical or biotechnology business establishment across the region are also contributing to the growth of alpha-1 antitrypsin deficiency therapy market share of this region. The market in this area is growing as people become more aware of various novel innovative therapies such as Prolastin-C. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global alpha-1 antitrypsin deficiency therapy market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for alpha-1 antitrypsin deficiency therapy in the U.S. United States have been proactive in executing several initiatives or researches, stimulating alpha-1 antitrypsin deficiency therapy demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global alpha-1 antitrypsin deficiency therapy market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for alpha-1 antitrypsin deficiency therapy. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global alpha-1 antitrypsin deficiency therapy market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like augmenting therapies and other programs for management of alpha-1 antitrypsin deficiency.

Key Developments

  • On May 23, 2023, data about the Phase 2 "ASTRAEUS" investigation of alvelestat for the management of Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD), along with post-hoc analyses illustrating the association among biomarker reductions using alvelestat and enhancements in SGRQ, a significant Patient-Reported Results (PRO) measure, have been presented for the very first time to the scientific world by Mereo BioPharma Group plc, a clinical-stage biopharmaceutical business focused on rare diseases.
  • On January 9, 2023, topline findings from the Phase 2 SEQUOIA research trial of the investigational drug fazirsiran (TAK-999/ARO-AAT) for the management of liver disease brought on by alpha-1 antitrypsin deficiency (AATD-LD) were disclosed by Takeda and Arrowhead Pharmaceuticals Inc. A Phase 3 study that was created jointly by Takeda and Arrowhead and would be carried out by Takeda was also outlined by the firms.

Competitive Landscape

The major global players in the market include: Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Inhibrx, Inc., Wave Life Sciences and Mereo Biopharma Group PLC among others.

Why Purchase the Report?

  • To visualize the global alpha-1 antitrypsin deficiency therapy market segmentation based on therapy, route of administration, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of alpha-1 antitrypsin deficiency therapy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global alpha-1 antitrypsin deficiency therapy market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing regulatory approvals for augmentation therapy
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the augmentation therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pricing Analysis
  • 5.6. SWOT Analysis
  • 5.7. Patent Analysis
  • 5.8. Russia-Ukraine War Impact Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 7.1.2. Market Attractiveness Index, By Therapy
  • 7.2. Augmentation Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Prolastin-C
    • 7.2.4. Aralast
    • 7.2.5. Zemaira
    • 7.2.6. Glassia
  • 7.3. Medication
    • 7.3.1. Bronchodilators
      • 7.3.1.1. Ipratropium Bromide
      • 7.3.1.2. Theophylline
    • 7.3.2. Antibiotics
      • 7.3.2.1. Doxycycline
      • 7.3.2.2. Dapsone
  • 7.4. Oxygen Therapy
  • 7.5. Smoking Cessation Therapy
  • 7.6. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Inhaled *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Kamada Pharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Takeda Pharmaceutical Company Limited
  • 12.3. CSL
  • 12.4. Vertex Pharmaceuticals Incorporated
  • 12.5. Grifols
  • 12.6. Arrowhead Pharmaceuticals, Inc.
  • 12.7. Dicerna Pharmaceuticals, Inc.
  • 12.8. Inhibrx, Inc.
  • 12.9. Wave Life Sciences
  • 12.10. Mereo Biopharma Group PLC

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us